MedReleaf
MedReleaf is a wholly owned subsidiary of Aurora Cannabis that produces and distributes EU-GMP and TGA-GMP certified medicinal cannabis under multiple brands across Australia and New Zealand, reaching patients through pharmacy wholesale partners Leafio and Vitura Health's Canview platform.
- Company typePrivate
- Founded2017
- HeadquartersMarkham, Canada
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What MedReleaf does
MedReleaf is a Canadian licensed producer of medical cannabis and a wholly owned subsidiary of Aurora Cannabis Inc. (NYSE: ACB), with the operational center of gravity shifted to its MedReleaf Australia entity serving Australia and New Zealand. It manufactures and distributes a full medicinal cannabis portfolio including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals, and operates a multi-brand shelf including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. Production is conducted at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using the parent company's proprietary cannabis genetics, which provides the pharmaceutical-grade quality assurance required to supply Australian and New Zealand regulated markets.
The business model is B2B-led rather than direct-to-consumer. In Australia, MedReleaf reaches patients through two parallel pharmacy-channel partnerships: Leafio, the wholesale distribution arm of Montu Australia, which services more than 4,000 pharmacies nationwide; and Vitura Health's Canview online platform, distributed through the Burleigh Heads Cannabis network across approximately 4,700 pharmacies, with Vitura estimating the deal could contribute up to $15 million in additional annual revenue. Marketing is concentrated in clinician education and product innovation rather than consumer advertising, and end customers are medical cannabis patients and the healthcare providers who prescribe to them. The company was originally founded in 2014 and was acquired by Aurora Cannabis in 2019, and the corporate, manufacturing, and distribution footprint is small (51-100 employees) relative to its pharmacy reach, reflecting a lean, channel-partner-driven operating model.
Underlying demand is supported by the global medical cannabis market context ($38.05 billion in 2025, growing at 18.84% CAGR per cited market data), with Australia cited as one of Aurora's largest international medical cannabis markets and recent product launches (THC flower in New Zealand, resin cartridges in Australia) extending the category mix. Revenue, pricing, and segment economics are not publicly disclosed at the MedReleaf level, leaving investor visibility dependent on parent Aurora's consolidated reporting and partner commentary such as Vitura's deal estimate.
MedReleaf firmographics
Firmographics- Name
- MedReleaf
- Legal name
- Aurora Cannabis Inc.
- Website
- https://medreleaf.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MedReleaf is a wholly owned subsidiary of Aurora Cannabis that produces and distributes EU-GMP and TGA-GMP certified medicinal cannabis under multiple brands across Australia and New Zealand, reaching patients through pharmacy wholesale partners Leafio and Vitura Health's Canview platform.
- Ownership category
- akta.pro rank
MedReleaf industry classification
Industry- Product category
- Medical Cannabis
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industries
- Medical Cannabis Delivery & Online Ordering (CRANAGAG), Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)
Keywords
Where MedReleaf is headquartered
LocationHeadquarters
- HQ city
- Markham
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
MedReleaf business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others
Revenue model
- Medicinal Cannabis Product Sales: MedReleaf generates revenue through the sale of its medicinal cannabis product portfolio including dried flower, oils, capsules, concentrates, vapes, edibles, and beverages under brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels1 record
MedReleaf product offering
Product offeringCore offering
MedReleaf is a Canadian licensed producer and distributor of medical cannabis, operating as a wholly owned subsidiary of Aurora Cannabis Inc. The company sells a full suite of medicinal cannabis products under brands including MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant — spanning dried flower, oils, capsules, concentrates, vapes, edibles, and beverages — manufactured at EU-GMP and TGA-GMP certified facilities and distributed through pharmacy networks in Australia and New Zealand.
Product overview
MedReleaf is a wholly owned subsidiary of Canadian-based Aurora Cannabis Inc. (NYSE: ACB) offering medicinal cannabis products under multiple brands including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. The company operates as part of Aurora's portfolio of medical cannabis brands distributed through various channels in Australia, New Zealand, and Canada. MedReleaf products span the full range of cannabis product formats including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals. Products are manufactured at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using proprietary genetics. Distribution partnerships with Leafio (4,000+ pharmacies) and Vitura Health's Canview platform (4,700+ pharmacies) expand patient access across Australia.
Differentiator
Problem solved
Functional benefit
Brands
- IndiMed: Medicinal cannabis brand under MedReleaf portfolio
- Whistler Cannabis Co.
- CraftPlant
- MedReleaf
Products and services
- MedReleaf brand medical cannabis products
- Aurora medical cannabis products
- IndiMed medicinal cannabis products
- Whistler Cannabis Co. medical cannabis products
- CraftPlant medical cannabis products
- New Zealand THC flower and Australia resin cartridges launch
Quantifiable outcome
- Up to $15 million potential additional annual revenue for distribution partner
- +1 more outcomes
Companies that use MedReleaf
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
MedReleaf technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MedReleaf partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Vitura HealthcoreVitura Health signed a commercial distribution agreement with MedReleaf Australia to make MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview online platform, distributed through the Burleigh Heads Cannabis nationwide network. Vitura estimates the deal could contribute up to $15 million in additional annual revenue, subject to patient demand and regulatory conditions.
- Leafio Australia (Montu)coreMedReleaf Australia's distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to medical cannabis products across Australia. Aurora's medical cannabis brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed will be distributed through Leafio's nationwide supply chain servicing over 4,000 pharmacies. The partnership aims to enhance clinician education, product innovation, and improve patient outcomes.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
MedReleaf competitors and assessment
Company assessmentDirect peers
- OrganiGram Holdings: Canadian licensed producer of medical cannabis, including a portfolio of dried flower, oils, and pre-rolls, with international distribution. Direct competitor in supplying Australian pharmacies with EU-GMP certified product.
- Cann Group Limited: Australian licensed medical cannabis cultivator and manufacturer. Comparable as a domestic producer supplying Australian pharmacy networks with medical-grade cannabis products, competing with MedReleaf's imported and locally distributed offerings.
- Little Green Pharma: Australian-based medical cannabis producer with strong domestic distribution through pharmacy networks. Competes directly with MedReleaf Australia for shelf space and prescriber relationships in the Australian market.
- Canopy Growth Corporation: Canadian licensed producer with international medical cannabis operations including Australia. Comparable in offering branded medical cannabis (dried flower, oils, capsules) into Australian pharmacy channels with similar distribution partnerships.
- Althea Group Holdings: Australian medical cannabis company producing and distributing a range of cannabis products (flower, oils, vapes) through pharmacy channels. Directly comparable in target customer (Australian patients), product formats, and pharmacy-led GTM.
- Tilray Brands: Global cannabis company with significant Australian medical cannabis distribution footprint through its Tilray Medical brand. Directly competes with MedReleaf in supplying EU-GMP medical cannabis to Australian pharmacy networks and prescribers.
Broad incumbents
- Aurora Cannabis Inc. Parent company of MedReleaf and a major global cannabis producer with operations across medical and consumer markets. Directly comparable as a medical cannabis cultivator and brand portfolio operator spanning dried flower, oils, capsules, vapes, and edibles.
- Cronos Group: Canadian-licensed cannabis producer with international medical cannabis ambitions and a multi-format product portfolio. Comparable as a peer Canadian LP with EU-GMP capabilities targeting international medical markets, though with less concentrated focus on Australia.
Emerging players
- Montu Group (parent of Leafio): Australian medical cannabis distribution and patient services company operating the Leafio wholesale network. While primarily a distributor and MedReleaf partner, Montu's vertical integration ambitions make it a comparable and potentially competing operator in the Australian medical cannabis channel.
- Vitura Health: Australian health and wellness company operating the Canview B2B platform and Burleigh Heads Cannabis pharmacy network. Functions as a key MedReleaf distribution partner, and its scale across 4,700+ Australian pharmacies makes it a critical peer in the medical cannabis distribution channel.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
MedReleaf social profiles
Digital presenceMedReleaf compliance and trust
Trust signalCompliance2 records
MedReleaf financial estimates
Financial estimateRevenue estimate
Valuation estimate
MedReleaf leadership team
Management profileNumber of profiles
Profiles4 records
MedReleaf subsidiaries and ownership
Company hierarchySubsidiaries1 record
MedReleaf funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MedReleaf M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MedReleaf
What does MedReleaf do?
MedReleaf is a Canadian licensed producer and distributor of medical cannabis, operating as a wholly owned subsidiary of Aurora Cannabis Inc. The company sells a full suite of medicinal cannabis products under brands including MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant — spanning dried flower, oils, capsules, concentrates, vapes, edibles, and beverages — manufactured at EU-GMP and TGA-GMP certified facilities and distributed through pharmacy networks in Australia and New Zealand.
Is MedReleaf a public or private company?
MedReleaf is a private company. It is classified as corporate owned and is currently operating.
When was MedReleaf founded?
MedReleaf was founded in 2017. It employs 51 to 100 people.
Where is MedReleaf based?
MedReleaf is headquartered in Markham, Canada, in the North America region.
How does MedReleaf make money?
One revenue line is on record: medicinal Cannabis Product Sales.
Who are MedReleaf's main competitors?
Direct peers on record are OrganiGram Holdings, Cann Group Limited, Little Green Pharma, Canopy Growth Corporation, Althea Group Holdings and Tilray Brands. Broad incumbents are Aurora Cannabis Inc. and Cronos Group. Emerging players are Montu Group (parent of Leafio) and Vitura Health.
Does MedReleaf have an API?
No public API is recorded for MedReleaf.
What industry is MedReleaf in?
MedReleaf's product category is Medical Cannabis. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 325411 and its SIC code is 2833.